Skip to main content
. Author manuscript; available in PMC: 2017 Aug 22.
Published in final edited form as: Med Biol Eng Comput. 2008 Jun 4;46(10):1039–1049. doi: 10.1007/s11517-008-0354-7

Figure 4.

Figure 4

Characteristics of simulated drug distribution with central implant, peripheral implants, or peripheral+central implants as a function of total DOX dose. Average doxorubicin concentration [DOX] over 8 days in (a) the entire tumor or (b) outer tumor rim (risk volume). (c) Simulated duration for which [DOX] ≥ 12.8 µg/g in entire risk volume. (d) Time after implantation at which [DOX] ≥ 12.8 µg/g in entire risk volume.